DelveInsight’s “Congenital Diarrheal Disorders Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Diarrheal Disorders market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Congenital Diarrheal Disorders drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Congenital Diarrheal Disorders treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Congenital Diarrheal Disorders: An Overview
Congenital diarrheal disorders (CDDs) are a group of inherited enteropathies with a typical onset early in life. Often, infants with these disorders present, early in life, with chronic diarrhea of sufficient severity to require parenteral nutrition support.
Milder forms with subtle clinical signs that remain undiagnosed until adulthood, when patients develop complications, are also possible for some conditions. There are various Congenital Diarrheal Disorders forms; some of them are congenital chloride diarrhea, congenital malabsorptive diarrhea, congenital sodium diarrhea, microvillus inclusion disease, and others.
CDDs arise from alterations in the transport of nutrients and electrolytes across the intestinal mucosa, from enterocyte and enteroendocrine cell differentiation and/or polarization defects, and from the modulation of the intestinal immune response. This disorder is majorly classified into four groups: (i) defects of digestion, absorption, and transport of nutrients and electrolytes; (ii) defects of enterocyte differentiation and polarization; (iii) defects of enteroendocrine cell differentiation; (iv) defects of modulation of the intestinal immune response.
Congenital Diarrheal Disorders Market Key Facts
-
As per National Organization for Rare Disorders (NORD) (n.d.), fewer than 100 cases of microvillus inclusion (MVID) have been reported in the medical literature. The true prevalence of this disorder is unknown. MVID affects more females than males with a sex ratio of about 2:1.
-
As per Wedenoja et al. (2009), the incidence of congenital chloride diarrhea is around 1:30,000
-
to 1:40,000, meaning one or two newborn patients annually. Other populations with a higher-than-average incidence are Polish (1:200,000), Kuwaiti, and Saudi Arabian.
-
As per the study titled “Congenital Diarrheal Disorders: An Updated Diagnostic Approach” conducted by Terrin et al. (2018), the exact incidence of most CDDs remains to be established, but in some cases, lysinuric protein intolerance (LPI) has a higher incidence either in Japan due to founder effect.
Congenital Diarrheal Disorders Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Congenital Diarrheal Disorders pipeline therapies. It also thoroughly assesses the Congenital Diarrheal Disorders market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Congenital Diarrheal Disorders drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Congenital Diarrheal Disorders Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Congenital Diarrheal Disorders epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Congenital Diarrheal Disorders epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Congenital Diarrheal Disorders Epidemiology, Segmented as –
-
Total Incident Cases of Congenital diarrheal disorders (CDDs)
-
Type-specific Incidence of Congenital diarrheal disorders (CDDs)
-
Treatable Cases of Congenital diarrheal disorders (CDDs)
Congenital Diarrheal Disorders Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Congenital Diarrheal Disorders market or expected to be launched during the study period. The analysis covers the Congenital Diarrheal Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Congenital Diarrheal Disorders drugs based on their sale and market share.
The report also covers the Congenital Diarrheal Disorders pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Congenital Diarrheal Disorders companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Congenital Diarrheal Disorders Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/congenital-diarrheal-disorders-market
Congenital Diarrheal Disorders Therapeutics Analysis
CDDs also involve congenital tufting enteropathy (CTE). CTE patients require daily, long-term parenteral support in order to maintain an adequate nutritional status. Life-threatening complications related to intestinal failure and long-term parenteral nutrition may become an indication for intestinal transplantation. There are various forms of CDDs, and each disorder has a specific and different treatment. In some cases, surgeries are
also needed to improve the condition depending upon the severity.
Therapies such as salt substitution therapy are used in the case of CLD to increase intestinal absorption by unspecified mechanisms and inhibit the development of hypochloremic and hypokalemic metabolic alkalosis. Despite the therapy, the defective SLC26A3‐mediated anion transport remains in the intestine, and the diarrhea is persistent. Although the relative amount of stools decreases with age, intestinal loss of electrolytes, and especially that of Cl), is continuous.
The pipeline for specifically targeted congenital diarrheal disorders (CDDs) therapies is not very robust as the treatment of CDDs depends on the cause, and treating the underlying factor will usually resolve the Congenital diarrheal disorders. Extensive research and development activities of pharmaceutical companies for developing therapies for Congenital diarrheal disorders will also significantly impact the market size and the treatment outlook.
Congenital Diarrheal Disorders Companies Emerging Therapies Analysis
Mytesi – Jaguar Health is working on developing Mytesi, a novel, a first‑in‑class anti‑secretory agent with a basic normalizing effect locally on the gut. This mechanism of action can benefit multiple gastrointestinal disorders. Jaguar, through Napo, holds extensive global rights for Mytesi. Mytesi is in development for multiple possible follow‑on indications, including diarrhea related to targeted cancer therapy; orphan‑drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea.
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/congenital-diarrheal-disorders-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Congenital Diarrheal Disorders Competitive Intelligence Analysis
4. Congenital Diarrheal Disorders Market Overview at a Glance
5. Congenital Diarrheal Disorders Disease Background and Overview
6. Congenital Diarrheal Disorders Patient Journey
7. Congenital Diarrheal Disorders Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Congenital Diarrheal Disorders Treatment Algorithm, Current Treatment, and Medical Practices
9. Congenital Diarrheal Disorders Unmet Needs
10. Key Endpoints of Congenital Diarrheal Disorders Treatment
11. Congenital Diarrheal Disorders Marketed Therapies
12. Congenital Diarrheal Disorders Emerging Drugs and Latest Therapeutic Advances
13. Congenital Diarrheal Disorders Seven Major Market Analysis
14. Attribute Analysis
15. Congenital Diarrheal Disorders Market Outlook (In US, EU5, and Japan)
16. Congenital Diarrheal Disorders Companies Active in the Market
17. Congenital Diarrheal Disorders Access and Reimbursement Overview
18. KOL Views on the Congenital Diarrheal Disorders Market
19. Congenital Diarrheal Disorders Market Drivers
20. Congenital Diarrheal Disorders Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/congenital-diarrheal-disorders-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Usher Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Usher Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Usher Syndrome market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/